Where does Denali Therapeutics Inc.'s income statement data come from?

Every line is extracted from Denali Therapeutics Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Research and development	$406.4M+0.2%	$418.78M+5.6%	$420.66M+4.0%	$416.95M+5.3%	$405.65M+0.9%
General and administrative	$140.72M+28.4%	$136.56M+29.5%	$127.16M+27.0%	$116.63M+16.0%	$109.56M+8.0%
Other operating expenses	$547.12M+6.2%	$555.34M+10.7%	$547.82M+8.6%	$533.58M+7.5%	$515.21M+2.3%
Total operating expenses	$547.12M+6.2%	$555.34M+10.7%	$547.82M+8.6%	$533.58M+7.5%	$515.21M+2.3%
Operating income	-$547.12M-6.2%	-$555.34M-14.0%	-$547.82M-11.8%	-$533.58M-11.0%	-$515.21M-166%
Interest income	$39.2M-36.1%	$42.9M-33.6%	$49.15M-21.5%	$54.61M-10.6%	$61.33M+8.8%
Net income	-$508.02M-11.9%	-$512.54M-21.2%	-$498.74M-16.7%	-$479.03M-14.1%	-$453.94M-231%
Diluted earnings per share	-$2.88-7.5%	-$2.97-15.1%	-$2.92-5.4%	-$2.81+1.7%	-$2.68-176%
Basic earnings per share	-$2.88-7.5%	-$2.97-15.1%	-$2.92-5.4%	-$2.81+1.7%	-$2.68-188%
Weighted-average shares, diluted	703.2M+4.3%	687.7M+5.5%	679.6M+8.7%	676.6M+14.0%	674M+19.2%
Weighted-average shares, basic	703.2M+4.3%	687.7M+5.5%	679.6M+8.7%	676.6M+14.0%	674M+20.0%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	-$510.74M-13.3%	-$513.88M-21.9%	-$503.17M-19.4%	-$475.44M-13.0%	-$450.61M-231%
Interest income and other, net	$39.2M-36.1%	$42.9M-33.6%	$49.15M-21.5%	$54.61M-10.6%	$61.33M+8.8%
Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax	-$2.72M—	-$1.34M—	——	——	——
EBIT	-$547.12M-6.2%	-$555.34M-14.0%	-$547.82M-11.8%	-$533.58M-11.0%	-$515.21M-166%
EBITDA	-$535.42M-5.6%	-$544.16M-13.5%	-$537.65M-11.6%	-$524.52M-11.1%	-$507.25M-175%
EBITDA	-$535.42M-5.6%	-$544.16M-13.5%	-$537.65M-11.6%	-$524.52M-11.1%	-$507.25M-175%
EBIT	-$547.12M-6.2%	-$555.34M-14.0%	-$547.82M-11.8%	-$533.58M-11.0%	-$515.21M-166%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Denali Therapeutics Inc.'s income statement data come from?: Every line is extracted from Denali Therapeutics Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.